The Universal Prescription for Parkinson's Disease: Exercise

Jay L Alberts, Anson B Rosenfeldt, Jay L Alberts, Anson B Rosenfeldt

Abstract

Over the past two decades, aerobic exercise has emerged as a mainstream recommendation to aid in treating Parkinson's disease (PD). Despite the acknowledgement of the benefits of exercise for people with PD (PwPD), frequently, exercise recommendations lack specificity in terms of frequency, intensity and duration. Additionally, conflating physical activity with exercise has contributed to providing vague exercise recommendations to PwPD. Therefore, the beneficial effects of exercise may not be fully realized in PwPD. Data provided by animal studies and select human trials indicate aerobic exercise may facilitate structural and functional changes in the brain. Recently, several large human clinical trials have been completed and collectively support the use of aerobic exercise, specifically high-intensity aerobic exercise, in improving PD motor symptoms. Data from these and other studies provide the basis to include aerobic exercise as an integral component in treating PD. Based on positive clinical findings and trials, it is advised that PwPD perform aerobic exercise in the following dose: 3x/week, 30-40-minute main exercise set, 60-80% of heart rate reserve or 70-85% of heart rate max. In lieu of heart rate, individuals can achieve an intensity of 14-17 on a 20-point RPE scale. Ongoing clinical trials, SPARX3 and CYCLE-II, have potential to further develop patient-specific exercise recommendations through prognostic modeling.

Keywords: Parkinson’s disease; aerobic exercise; exercise; physical activity.

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1
Potential phenotyping of participant response to exercise based on exercise performance and demographic 3D model variables. Individuals are classified as non-responders, neutral, and responders based on change in the MDS-UPDRS III score over the course of the exercise intervention. The model postulates that individuals with greater cadence, HR compliance, and shorter disease duration will experience improved symptom management as measured by the MDS-UPDRS III.

References

    1. Parkinson’s disease Foundation, Statistics on Parkinson’s, , Accessed March 30, 2020.
    1. GBD Neurological Disorders Collaborator Group (2017) Global, regional, and national burden of neurological disorders during 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 16, 877–897.
    1. Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287, 1653–1661.
    1. Fahn S, Parkinson Study Group (2005) Does levodopa slow or hasten the rate of progression of Parkinson’s disease?. J Neurol 252(Suppl 4), IV37–IV42.
    1. Petzinger GM, Fisher B, Hogg E, Abernathy A, Arevalo P, Nixon K, Jakowec MW (2006) Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): Changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins. J Neurosci Res 83, 332–347.
    1. Petzinger GM, Fisher BE, Van Leeuwen JE, Vukovic M, Akopian G, Meshul CK, Holschneider DP, Nacca A, Walsh JP, Jakowec MW (2010) Enhancing neuroplasticity in the basal ganglia: The role of exercise in Parkinson’s disease. Mov Disord 25(Suppl 1), S141–145.
    1. Petzinger GM, Walsh JP, Akopian G, Hogg E, Abernathy A, Arevalo P, Turnquist P, Vuckovic M, Fisher BE, Togasaki DM, Jakowec MW (2007) Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J Neurosci 27, 5291–5300.
    1. Zigmond MJ, Cameron JL, Leak RK, Mirnics K, Russell VA, Smeyne RJ, Smith AD (2009) Triggering endogenous neuroprotective processes through exercise in models of dopamine deficiency. Parkinsonism Relat Disord 15(Suppl 3), S42–45.
    1. Tajiri N, Yasuhara T, Shingo T, Kondo A, Yuan W, Kadota T, Wang F, Baba T, Tayra JT, Morimoto T, Jing M, Kikuchi Y, Kuramoto S, Agari T, Miyoshi Y, Fujino H, Obata F, Takeda I, Furuta T, Date I (2010) Exercise exerts neuroprotective effects on Parkinson’s disease model of rats. Brain Res 1310, 200–207.
    1. Tillerson JL, Caudle WM, Reveron ME, Miller GW (2003) Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson’s disease. Neuroscience 119, 899–911.
    1. van der Kolk NM, de Vries NM, Kessels RPC, Joosten H, Zwinderman AH, Post B, Bloem BR (2019) Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson’s disease: A double-blind, randomised controlled trial. Lancet Neurol 18, 998–1008.
    1. Schenkman M, Moore CG, Kohrt WM, Hall DA, Delitto A, Comella CL, Josbeno DA, Christiansen CL, Berman BD, Kluger BM, Melanson EL, Jain S, Robichaud JA, Poon C, Corcos DM (2018) Effect of high-intensity treadmill exercise on motor symptoms in patients with de novo Parkinson disease: A phase 2 randomized clinical trial. JAMA Neurol 75, 219–226.
    1. World Health Organization, Physical Activity and Older Adults, , Accessed April 14, 2020.
    1. Hallal PC, Andersen LB, Bull FC, Guthold R, Haskell W, Ekelund U, Lancet Physical Activity Series Working Group (2012) Global physical activity levels: Surveillance progress, pitfalls, and prospects. Lancet 380, 247–257.
    1. van Nimwegen M, Speelman AD, Hofman-van Rossum EJ, Overeem S, Deeg DJ, Borm GF, van der Horst MH, Bloem BR, Munneke M (2011) Physical inactivity in Parkinson’s disease. J Neurol 258, 2214–2221.
    1. Cavanaugh JT, Ellis TD, Earhart GM, Ford MP, Foreman KB, Dibble LE (2015) Toward understanding ambulatory activity decline in Parkinson disease. Phys Ther 95, 1142–1150.
    1. Bouca-Machado R, Rosario A, Caldeira D, Castro Caldas A, Guerreiro D, Venturelli M, Tinazzi M, Schena F, Ferreira JJ (2020) Physical activity, exercise, and physiotherapy in Parkinson’s disease: Defining the concepts. Mov Disord Clin Pract 7, 7–15.
    1. Caspersen CJ, Powell KE, Christenson GM (1985) Physical activity, exercise, and physical fitness: Definitions and distinctions for health-related research. Public Health Rep 100, 126–131.
    1. Goetz CG (1986) Charcot on Parkinson’s disease. Mov Disord 1, 27–32.
    1. Charcot JM (1892) Vibratory therapeutics.–The application of rapid and continuous vibrations to the treatment of certain diseases of the nervous system. J Nerv Ment Dis 17, 880–886.
    1. Kapur SS, Stebbins GT, Goetz CG (2012) Vibration therapy for Parkinson’s disease: Charcot’s studies revisited. J Parkinsons Dis 2, 23–27.
    1. Gowers WR (1892) A Manual of Diseases of the Nervous System, 2nd Ed, Vol. 1, P. Blakiston, Son & Co., Philadelphia.
    1. Clark EC, Mulder DW, Erickson DJ, Clements BG, Maccarty CS (1957) Parkinson’s disease: Therapeutic exercises in its management. Postgrad Med 21, 301–308.
    1. Clark EC, Clements BG, Erickson DJ, Maccarty CS, Mulder DW (1956) Therapeutic exercises in management of paralysis agitans. J Am Med Assoc 162, 1041–1043.
    1. Van Oteghen SL (1987) An exercise program for those with Parkinson’s disease. Geriatr Nurs 8, 183–184.
    1. Wroe M, Greer M (1973) Parkinson’s disease and physical therapy management. Phys Ther 53, 849–855.
    1. Tolosa E, Marti MJ, Valldeoriola F, Molinuevo JL (1998) History of levodopa and dopamine agonists in Parkinson’s disease treatment. Neurology 50, S2-10; discussion S44–18.
    1. Ahlskog JE (2011) Does vigorous exercise have a neuroprotective effect in Parkinson disease?. Neurology 77, 288–294.
    1. Cohen AD, Tillerson JL, Smith AD, Schallert T, Zigmond MJ (2003) Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: Possible role of GDNF. J Neurochem 85, 299–305.
    1. Thacker EL, Chen H, Patel AV, McCullough ML, Calle EE, Thun MJ, Schwarzschild MA, Ascherio A (2008) Recreational physical activity and risk of Parkinson’s disease. Mov Disord 23, 69–74.
    1. Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A (2005) Physical activity and the risk of Parkinson disease. Neurology 64, 664–669.
    1. Fisher BE, Petzinger GM, Nixon K, Hogg E, Bremmer S, Meshul CK, Jakowec MW (2004) Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- lesioned mouse basal ganglia. J Neurosci Res 77, 378–390.
    1. Erickson KI, Leckie RL, Weinstein AM (2014) Physical activity, fitness, and gray matter volume. Neurobiol Aging 35(Suppl 2), S20–28.
    1. Dougherty RJ, Ellingson LD, Schultz SA, Boots EA, Meyer JD, Lindheimer JB, Van Riper S, Stegner AJ, Edwards DF, Oh JM, Koscik RL, Dowling MN, Gallagher CL, Carlsson CM, Rowley HA, Bendlin BB, Asthana S, Hermann BP, Sager MA, Johnson SC, Okonkwo OC, Cook DB (2016) Meeting physical activity recommendations may be protective against temporal lobe atrophy in older adults at risk for Alzheimer’s disease. Alzheimers Dement (Amst) 4, 14–17.
    1. Voss MW, Erickson KI, Prakash RS, Chaddock L, Malkowski E, Alves H, Kim JS, Morris KS, White SM, Wojcicki TR, Hu L, Szabo A, Klamm E, McAuley E, Kramer AF (2010) Functional connectivity: A source of variance in the association between cardiorespiratory fitness and cognition?. Neuropsychologia 48, 1394–1406.
    1. Alberts JL, Phillips M, Lowe MJ, Frankemolle A, Thota A, Beall EB, Feldman M, Ahmed A, Ridgel AL (2016) Cortical and motor responses to acute forced exercise in Parkinson’s disease. Parkinsonism Relat Disord 24, 56–62.
    1. Beall EB, Lowe MJ, Alberts JL, Frankemolle AM, Thota AK, Shah C, Phillips MD (2013) The effect of forced-exercise therapy for Parkinson’s disease on motor cortex functional connectivity. Brain Connect 3, 190–198.
    1. Shah C, Beall EB, Frankemolle AM, Penko A, Phillips MD, Lowe MJ, Alberts JL (2016) Exercise therapy for Parkinson’s disease: Pedaling rate is related to changes in motor connectivity. Brain Connect 6, 25–36.
    1. Fisher BE, Li Q, Nacca A, Salem GJ, Song J, Yip J, Hui JS, Jakowec MW, Petzinger GM (2013) Treadmill exercise elevates striatal dopamine D2 receptor binding potential in patients with early Parkinson’s disease. Neuroreport 24, 509–514.
    1. Duchesne C, Gheysen F, Bore A, Albouy G, Nadeau A, Robillard ME, Bobeuf F, Lafontaine AL, Lungu O, Bherer L, Doyon J (2016) Influence of aerobic exercise training on the neural correlates of motor learning in Parkinson’s disease individuals. Neuroimage Clin 12, 559–569.
    1. Herman T, Giladi N, Gruendlinger L, Hausdorff JM (2007) Six weeks of intensive treadmill training improves gait and quality of life in patients with Parkinson’s disease: A pilot study. Arch Phys Med Rehabil 88, 1154–1158.
    1. Ridgel AL, Vitek JL, Alberts JL (2009) Forced, not voluntary, exercise improves motor function in Parkinson’s disease patients. Neurorehabil Neural Repair 23, 600–608.
    1. Fisher BE, Wu AD, Salem GJ, Song J, Lin CH, Yip J, Cen S, Gordon J, Jakowec M, Petzinger G (2008) The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinson’s disease. Arch Phys Med Rehabil 89, 1221–1229.
    1. Uc EY, Doerschug KC, Magnotta V, Dawson JD, Thomsen TR, Kline JN, Rizzo M, Newman SR, Mehta S, Grabowski TJ, Bruss J, Blanchette DR, Anderson SW, Voss MW, Kramer AF, Darling WG (2014) Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting. Neurology 83, 413–425.
    1. Moore CG, Schenkman M, Kohrt WM, Delitto A, Hall DA, Corcos D (2013) Study in Parkinson disease of exercise (SPARX): Translating high-intensity exercise from animals to humans. Contemp Clin Trials 36, 90–98.
    1. van der Kolk NM, Overeem S, de Vries NM, Kessels RP, Donders R, Brouwer M, Berg D, Post B, Bloem BR (2015) Design of the Park-in-Shape study: A phase II double blind randomized controlled trial evaluating the effects of exercise on motor and non-motor symptoms in Parkinson’s disease. BMC Neurol 15, 56.
    1. Riebe D, Franklin BA, Thompson PD, Garber CE, Whitfield GP, Magal M, Pescatello LS (2015) Updating ACSM’s Recommendations for Exercise Preparticipation Health Screening. Med Sci Sports Exerc 47, 2473–2479.
    1. Nadeau A, Pourcher E, Corbeil P (2014) Effects of 24 wk of treadmill training on gait performance in Parkinson’s disease. Med Sci Sports Exerc 46, 645–655.
    1. Penko AL, Barkley JE, Koop MM, Alberts JL (2017) Borg scale is valid for ratings of perceived exertion for individuals with Parkinson’s disease. Int J Exerc Sci 10, 76–86.
    1. American College of Sports Medicine (ACSM) (2018) ACSM’s Guidelines for Exercise Testing and Prescription, Lippincott Williams & Wilkins, Philadelphia.
    1. Klanbut S, Phattanarudee S, Wongwiwatthananukit S, Suthisisang C, Bhidayasiri R (2018) Symptomatic orthostatic hypotension in Parkinson’s disease patients: Prevalence, associated factors and its impact on balance confidence. J Neurol Sci 385, 168–174.
    1. Mehrholz J, Kugler J, Storch A, Pohl M, Hirsch K, Elsner B (2015) Treadmill training for patients with Parkinson’s disease. Cochrane Database Syst Rev, CD007830.
    1. Kang GA, Bronstein JM, Masterman DL, Redelings M, Crum JA, Ritz B (2005) Clinical characteristics in early Parkinson’s disease in a central California population-based study. Mov Disord 20, 1133–1142.
    1. Harrell FE (2015) Regression Modeling Strategies with Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis, 2nd Ed, Springer, Heidelberg.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する